Hypertension control and kidney disease: Some questions answered, many remain

JAMA

Volumn 288, Issue 19, 2002, Pages 2466-2467

  Alderman, Michael H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE REGULATION; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEINURIA;

EID: 0037145816     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.19.2466     Document Type: Editorial

References (14)

1. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002;288:2421-2431.
2. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
3. Wright JT Jr, Kusek JW, Toto RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17(suppl 4):3S-16S.
4. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461-470.
5. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA. 1992;268:3085-3091.
6. Blood Pressure Lowering Treatment Trialists Group. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
7. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719-2728.
8. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet. 2000;356:1955-1964.
9. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet. 1995;345:749-751.
10. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomized trial against atenolol. Lancet. 2002; 359:1004-1010.
11. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
12. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet. 2000;356:1949-1954.
13. Ooi WL, Budner NS, Cohen H, Madhavan S, Alderman MH. Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension. 1989;14:227-234.
14. Zarif L, Covic A, Iyengar S, et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant. 2000;15:1801-1807.